Navigation Links
One-Year European Registry Data Released for Popliteal Stenting With SUPERA®
Date:2/8/2011

LEIPZIG, Germany, Feb. 8, 2011 /PRNewswire/ -- Data from the Leipzig Registry tracking the results of patients treated with the SUPERA® stent for peripheral arterial disease (PAD) of the popliteal artery were reported during the recent 2011 Leipzig Interventional Course (LINC).  The SUPERA stent is CE marked for biliary and peripheral vascular use in Europe.  In the United States the SUPERA stent is the subject of an ongoing FDA-approved IDE trial called SUPERB (Comparison of the SUPERA PERipheral System to a Performance Goal Derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery) for treatment of PAD of the superficial femoral artery (SFA).

Dr. Andrej Schmidt of the Department of Angiology at Park Hospital and Heart Center in Leipzig presented the 12-month European data.  The 101 patients treated at Park Hospital had advanced PAD.  Nearly a third of the patients were classified as Rutherford 4 or 5, and almost 50 percent had an occlusion of the popliteal artery.  The average stent length within the registry was approximately 8.5 centimeters.

The primary patency rate, measured by duplex ultrasonography, was 87 percent at 12 months.  In addition, there were no stent fractures detected by x-ray at an average of 13.3 months.

"The SUPERA stent has become our stent of choice," commented Dr. Schmidt.  "No standard nitinol stent provides the same level of flexibility and radial strength, and both characteristics are necessary to conform to and support the SFA and popliteal anatomy."

"SUPERA is a different class of stent, and is exhibiting remarkable long-term durability in extremely diseased patients," commented Richard C. Kovach, M.D. and Chair, Department of Endovascular Medicine and Director, Cardiac Catheterization Laboratory at Deborah Heart and Lung Center in Browns Mills, New Jersey.  "There were several presentations and live cases throughout LINC highlighting ho
'/>"/>

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohns Disease
6. Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
10. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
11. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic ... Tom Koob , Ph.D., Chief Scientific Officer, will present ... Koob will present on Tuesday, October 7, 2014, at ...
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... DENVER , Sept. 30, 2014  According ... "the world of cancer clinical trials is going ... clinical trials and the work of the current ... these types of ,next generation, clinical trials, which ... tomorrow."  The company has been ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... Reportlinker.com announces that a new market research ... Neurostimulation Devices - Global Pipeline ... 2016 http://www.reportlinker.com/p0285077/Neurostimulation-Devices---Global-Pipeline-Analysis--Opportunity-Assessment-and-Market-Forecasts-to-2016.html ... Pipeline Analysis, Opportunity Assessment and Market Forecasts ...
... announces that a new market research report is ... Dysfunction - Pipeline Assessment and Market Forecasts to ... Erectile Dysfunction - Pipeline Assessment and Market ... and healthcare report, "Erectile Dysfunction - Pipeline Assessment ...
Cached Medicine Technology:Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 11Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017 6
(Date:10/1/2014)... October 01, 2014 Insuranceragents.info has ... a good life insurance plan for vulnerable family members. ... vulnerable family members. Providers in the family should always ... cause financial hardships for the rest of the family. ... policies. Families can benefit more from temporary coverage or ...
(Date:10/1/2014)... First Warning Systems, a pioneer in early cancer ... body, announced the company is changing its name to ... of upcoming product releases. The initial focus will be ... initial focus will be an ‘Internet of Everthing,’ wearable ... changes over time,” said Rob Royea, president and CEO ...
(Date:10/1/2014)... FARMINGTON, Conn. (PRWEB) October 01, 2014 ... its company, including a redefined mission and visual ... the power of partnering with them to create ... more agile brand that focuses on empowering customers ... benefits communications. , The crown jewel of the ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... has opened the way for a new generation of drugs to ... tumors. ,Scientists have carried out the widest survey ... findings will be used to design anti-cancer drugs targeted at counteracting ... to result from an accumulation of mutations in one or another ...
... found naturally in oily fish, could help develop their brain, ... ,Professor Basant Puri from Imperial College, London, carried out ... and 13, who were overweight, reported the online edition of ... to look at the effects of junk food on young ...
... an extension of the advice most of us have grown ... research has suggested that beta carotene pills may not be ... related macular degeneration is common amongst the older generation, which ... might seem like a bolt from the blue, but carrots, ...
... – A certain batch of peanut butter, bought as early ... been ordered// off the shelf by the U.S. Food and ... butter is behind the outbreak of salmonella. ,Earlier, ... Peter Pan peanut butter bought since May 2006, including the ...
... be possible to wipe out memories selectively from the human ... have been able// to wipe out a single specific memory ... recollections intact. ,If that experiment can be ... be possible to help relieve sufferers of the Post-traumatic Stress ...
... reported thirteen fresh cases of bird flu, taking the total ... Assadullah Azhari, a spokesman for the United Nations Food and ... to suffer the lethal H5N1 strain of bird flu. ... forbidden the import of poultry products from Pakistan and other ...
Cached Medicine News:Health News:Gene Study Offers Hope of Potent Anti-cancer Drugs 2
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the quantitative determination of alkaline phosphatase in human serum....
Medicine Products: